BEIGF News and Press, BeiGene From 05/26/25

2025-05-26 10:32:36 ET Summary Despite a sharp decline in sales of COVID-19 blockbuster Veklury, Gilead Sciences once again beat consensus revenue and EPS forecasts. The drugs whose performance impressed me greatly in Q1 2025 and which played a key role in maintaining Gilead's EBI...

2025-05-22 08:05:00 ET Summary Global equity markets diverged in Q1 2025, with U.S. equities underperforming due to aggressive tariffs and geopolitical tensions, while Europe and China showed resilience. Our investment strategy emphasizes long-term secular growth trends, strong co...

2025-05-12 13:05:26 ET Summary The 'Undercovered' Dozen series highlights 12 lesser-covered stocks weekly, providing investment ideas and sparking community discussion on their potential. Graham Corporation and Legal & General Group Plc are recommended as buys due to strong ba...

2025-05-09 05:37:08 ET Summary The Biotech industry has underperformed due to Trump administration, RFK Jr's skepticism, and funding uncertainty, with major ETFs down 19-25% over six months. Some biotech companies with approved products and successful rollouts have outperformed, h...

2025-05-08 09:24:42 ET Summary BeiGene, Ltd., soon to be BeOne Medicines, is a global oncology company with a strong focus on innovative cancer treatments, particularly Brukinsa and Tevimbra. Brukinsa, a BTK inhibitor, has shown impressive revenue growth and market share gains, wi...

2025-05-07 14:05:03 ET More on BeiGene, Ltd., BeiGene, etc. BeiGene, Ltd. (ONC) Q1 2025 Earnings Call Transcript BeiGene: Q4 Results Impress With Positive Earnings Expected In 2025 BeiGene, Ltd. (ONC) Q4 2024 Earnings Call Transcript BeiGene reports mixed Q1 ...

2025-05-07 14:04:09 ET BeiGene, Ltd. (ONC) Q1 2025 Results Conference Call May 07, 2025 08:00 AM ET Company Participants Dan Maller - Head, Investor Relations John Oyler - Co-Founder, Chairman & Chief Executive Officer Xiaobin Wu - President & Chief Opera...

2025-05-07 06:16:23 ET More on BeiGene, Ltd. BeiGene, Ltd. (ONC) Q4 2024 Earnings Call Transcript Historical earnings data for BeiGene, Ltd. Financial information for BeiGene, Ltd. Read the full article on Seeking Alpha For further details see: Be...

2025-04-03 17:54:49 ET Summary ImmunityBio, Inc.'s recent progress on Anktiva and rBCG, including FDA submissions and collaborations, positions the company for significant revenue growth despite current financial challenges. The severe BCG shortage impacts Anktiva's growth, but Im...

2025-03-12 23:56:16 ET Summary Baker Brothers' 13F portfolio value decreased from $9.65B to $9.36B, with 26 significant positions making up the majority of the portfolio. The top five holdings—Incyte, BeiGene, ACADIA Pharma, Madrigal Pharma, and Insmed—constitute app...